Navigation Links
Portola Pharmaceuticals Presents Positive Phase I Data of Its ADP,Receptor Antagonist at the American College of Cardiology

NEW ORLEANS, March 28, 2007 /PRNewswire/ -- Portola Pharmaceuticals, Inc. presented Phase I data of its ADP receptor antagonist at the of Cardiology's (ACC) 56th Annual Scientific Session this week. Portola's reversible antiplatelet compound, PRT060128, appeared safe and well-tolerated in this study and achieved high-level platelet inhibition.

Portola presented the data in a poster session titled "First in Human Experience with PRT060128, a New Direct-acting, Reversible P2Y(12) Inhibitor for IV and Oral Use" which describes the single ascending dose (SAD) study of the oral formulation of PRT060128. In this study, dose dependent and full inhibition of ADP-induced platelet aggregation was achieved. In addition, following administration of PRT060128, inhibition of platelet aggregation was fully reversed within 24 hours post dosing. All doses of PRT060128 were well tolerated. There were no serious adverse events and no discontinuations due to an adverse event.

"Successful results from both our Phase I oral and intravenous studies build a strong foundation for advancing PRT060128 in the clinic," said Dan Gretler, MD, Portola's vice president of Clinical Development and Regulatory Affairs. "We will initiate our Phase II clinical program later this year to further study the differentiated properties of our ADP receptor antagonist."

Portola's ADP Receptor Antagonist

PRT060128 is an antiplatelet drug that is the only intravenous (IV) and oral ADP receptor antagonist in clinical development. Portola believes that this compound may provide significant clinical benefit through immediate, high-level platelet inhibition in the acute setting and a seamless transition to predictable, reversible platelet inhibition in the chronic setting. Portola has studied this compound in a robust Phase I clinical development program including single ascending dose and multiple ascending dose studies with the oral
'"/>




Page: 1 2

Related medicine technology :

1. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
3. Portola Pharmaceuticals Announces Positive Phase II Results for PRT054021 for Prevention of Venous Thromboembolism Following Total Knee Replacement Surgery
4. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Cyclacel Pharmaceuticals Announces Results of Phase II Seliciclib Combination Studies
Post Your Comments:
(Date:5/22/2015)... According to a new market research report ... by Test Type (Indirect, Enzyme-based, Reactive Oxygen Species (ROS)-based), ... - Global Forecast to 2020", published by MarketsandMarkets, the global ... Million by 2020 from $452.36 Million in 2015, growing ... 71 market data Tables and 90 Figures spread through ...
(Date:5/22/2015)... 2015 Today, Rhodes Pharmaceuticals L.P. announced that ... indicated for the treatment of Attention-Deficit/Hyperactivity Disorder (ADHD) ... The announcement comes just one ... U.S. Food and Drug Administration (FDA). ... methylphenidate capsule with an onset of effect of ...
(Date:5/22/2015)... , May 22, 2015  China Nepstar Chain ... a leading retail drugstore chain in China ... stores, today announced the resignation of Mr. Fuxiang ... personal reasons, effective immediately. Ms. Rebecca Yingnan Zhang ... the Company,s board of directors, effective immediately. Meanwhile, Ms. ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 2Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 3Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 4Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 5Rhodes Pharmaceuticals Announces Launch of New, Once-Daily Treatment for ADHD 6China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 2China Nepstar Chain Drugstore Ltd. Announces Management Change and New Director Appointment 3
... Results of two studies testing drugs to slow or ... people newly diagnosed with type 1 diabetes will be ... Sessions in San Diego and simultaneously published online in ... the National Institutes of Health,s international network of researchers, ...
... Inc., a clinical-stage epigenetics oncology company, today announced that ... tumor reprogramming will be presented at the International Association ... Conference on Lung Cancer meeting ( www.2011worldlungcancer.org ) July ... "The data presentations from both lung cancer programs ...
Cached Medicine Technology:Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 2Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 3Two Studies Test Impact of Drugs to Slow Progression of Type 1 Diabetes 4Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference 2Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference 3Syndax Pharmaceuticals Announces Entinostat Data from Two Lung Cancer Clinical Trials at Upcoming World Lung Conference 4
(Date:5/23/2015)... 23, 2015 On Saturday, May 23, 2015, ... playground for Branches Florida City exactly five years to the ... in 2010. , A large fire tore through the Branches ... 23, 2010 in the middle of the night as neighbors, ... later declared arson even though it is suspected that the ...
(Date:5/23/2015)... May 23, 2015 On May 16, the ... The event was a 5k mud obstacle run that raised ... 2 million people worldwide, and the reason we participated was ... Chad Davis, owner of Farrell’s eXtreme Bodyshaping. “One-hundred percent of ... Society.” , The event was not only attended by eXtreme ...
(Date:5/23/2015)... 23, 2015 Injury lawyer Steven H. Heisler ... passed by the Maryland legislature but which has not been ... Assembly passed HB 449 with overwhelming bipartisan support ... signed it into law. This bill ensures that fracking is ... that demonstrates the danger of fracking to our water supplies ...
(Date:5/22/2015)... 22, 2015 River Valley Health Partners ... the health system’s Chief Financial Officer (CFO), will be ... served as the company CFO since 2011. , The ... joining the health system as CFO. Wesley will oversee ... while the Board of Trustees conducts a formal search ...
(Date:5/22/2015)... (PRWEB) May 22, 2015 Hands On ... June 17, 2015, the Annual One Day Sale ... 2007, Hands On HCMT offers drastically reduced certificates one day ... estheticians have enough sessions, through what used to be the ... wonderful for the community as well. This once a year ...
Breaking Medicine News(10 mins):Health News:Five Years After Fire, Branches Rebuilds Playground 2Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 2Health News:Baltimore Attorney Urges Governor Hogan to Sign the Fracking Moratorium Bill 3Health News:River Valley Health Partners Announces CFO Transition, Appointment of Interim CFO 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 2Health News:Hands On HealthCare Massage Therapy & Wellness Day Spa Announces Their Eighth Annual One Day Sale on Gift Certificates Will Take Place on June 17, 2015 3
... Drug Administration announced that Vioxx - Merck's blockbuster painkiller, ... said that Merck can claim that Vioxx has fewer ... But the FDA also decided that the Vioxx label ... increased risk of heart attack or high blood pressure. ...
... study, Vitamin C and E supplements protect the coronary ... be a life-saver// but, the vessels linking the new ... only a way could be found of blocking this ... Hopkins Hospital in Boston, US, believe that they have ...
... is a chronic neurological disorder in which misfiring electrical ... million Americans have epilepsy, and more than a million ... a significant risk that their children will have problems ... new study adds to growing evidence that many commonly ...
... Carolina at Chapel Hill, state about the discovery of how ... The UNC scientists have found a previously unknown ... the genetic messenger known as RNA. When the chemical ... which the information contained in DNA,is converted into functions critical ...
... to munching his way through 50 ballpoint pens a week has ... a month on his habit after he was banned// from using ... to write with. “My manager took me one side ... but the fact that nobody else could ever find a pen ...
... their daily exercise time in order to control their weight. ... day// of moderate exercise for health and weight control. But ... that this may not be enough. ,They have ... gain weight. Physical inactivity alone accounted for 60 per cent ...
Cached Medicine News:
... The APTIMA COMBO 2 Assay is ... that uses target capture for in vitro ... CT and GC. The assay uses a ... capture (TC), Transcription-Mediated Amplification (TMA) and Dual ...
Rapid Test Kit...
... the only rapid test designed specifically for ... pH in one device. Fecal occult ... when used with gastric specimens. This ... and management of various gastric conditions which ...
... Sunrise Technologies has developed laser thermal keratoplasty ... June 30, 2000 for the temporary reduction of ... 40 years and older with up to 0.75 ... previous 6 months. Unlike most refractive surgery, ...
Medicine Products: